Jeffrey E. Lancet

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes et al. · Journal of Clinical Oncology · 2018 · 958 citations · Full text

Mixed-phenotype Acute Leukemia, Pharmacotherapy, Metronomic Chemotherapy +16

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Margaret O’Donnell, Martin S. Tallman, Camille N. Abboud et al. · Journal of the National Comprehensive Cancer Network · 2017 · 651 citations · Full text

Hematological Malignancy, Version 3.2017, Oncology +14

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

Judith E. Karp, Jeffrey E. Lancet, Scott H. Kaufmann et al. · Blood · 2001 · 445 citations · Full text

Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes

David A. Sallman, Amy E. DeZern, Guillermo Garcia‐Manero et al. · Journal of Clinical Oncology · 2021 · 436 citations · Full text

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Martin S. Tallman, Eunice S. Wang, Jessica K. Altman et al. · Journal of the National Comprehensive Cancer Network · 2019 · 418 citations

Hematological Malignancy, Health Sciences, Medicine +15